| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Alessandro Beghini | |
| P2860 | cites work | Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFbeta | Q22254263 |
| Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation | Q24300183 | ||
| Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia | Q24311601 | ||
| The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity | Q24317706 | ||
| A novel epigenetic AML1-ETO/THAP10/miR-383 mini-circuitry contributes to t(8;21) leukaemogenesis | Q41569195 | ||
| CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. | Q42444092 | ||
| CHD7 deficiency delays leukemogenesis in mice induced by CBFB-MYH11. | Q42778080 | ||
| Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells | Q43567027 | ||
| KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication | Q45038431 | ||
| Alternative RUNX1 Promoter Regulation by Wnt/β-Catenin Signaling in Leukemia Cells and Human Hematopoietic Progenitors. | Q45345502 | ||
| The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo | Q45345510 | ||
| Revision of the human hematopoietic tree: granulocyte subtypes derive from distinct hematopoietic lineages. | Q45899964 | ||
| Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway | Q46350435 | ||
| Epigenetic role of miRNAs in normal and leukemic hematopoiesis | Q46608275 | ||
| Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. | Q48860347 | ||
| The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. | Q50335773 | ||
| Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. | Q52187583 | ||
| Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. | Q52524249 | ||
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). | Q52569827 | ||
| AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. | Q53223182 | ||
| ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors | Q24522848 | ||
| MicroRNA fingerprints during human megakaryocytopoiesis | Q24546361 | ||
| Oligomerization of ETO is obligatory for corepressor interaction | Q24550754 | ||
| The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain | Q24554277 | ||
| Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis | Q24567977 | ||
| A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? | Q24629627 | ||
| ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex | Q24653699 | ||
| CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control | Q24676449 | ||
| Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities | Q26863756 | ||
| Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity | Q27664050 | ||
| A stable transcription factor complex nucleated by oligomeric AML1–ETO controls leukaemogenesis | Q27678844 | ||
| RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years | Q27824840 | ||
| Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study | Q27824856 | ||
| MicroRNA signatures in human cancers | Q27860962 | ||
| A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia | Q28141676 | ||
| AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis | Q28273478 | ||
| Regulation of progenitor cell proliferation and granulocyte function by microRNA-223 | Q28510667 | ||
| Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations | Q28590040 | ||
| Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor | Q28594445 | ||
| Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia | Q28821250 | ||
| RNA maps reveal new RNA classes and a possible function for pervasive transcription | Q29614334 | ||
| miRNAs, cancer, and stem cell division | Q29618925 | ||
| A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis | Q29619201 | ||
| Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis | Q30309829 | ||
| Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo | Q30413034 | ||
| Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1 | Q30432285 | ||
| CBFbeta is critical for AML1-ETO and TEL-AML1 activity | Q30439864 | ||
| Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta | Q30530806 | ||
| Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup | Q30950217 | ||
| PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis | Q32884406 | ||
| AML1 deletion in adult mice causes splenomegaly and lymphomas. | Q33369036 | ||
| Comprehensive mutational profiling of core binding factor acute myeloid leukemia | Q33758306 | ||
| AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. | Q33762738 | ||
| The genomic landscape of core-binding factor acute myeloid leukemias | Q33901968 | ||
| AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion | Q33932435 | ||
| AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations | Q33943238 | ||
| Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia | Q34048276 | ||
| Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles | Q34098676 | ||
| Comprehensive microRNA expression profiling of the hematopoietic hierarchy | Q34100287 | ||
| Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. | Q34106837 | ||
| Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias | Q34169601 | ||
| Genetic alterations of the cohesin complex genes in myeloid malignancies. | Q34170374 | ||
| MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation | Q34212635 | ||
| AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis | Q34299077 | ||
| Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits | Q34300594 | ||
| Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission | Q34405195 | ||
| DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. | Q34433577 | ||
| Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study | Q34570206 | ||
| C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice | Q34572894 | ||
| Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts | Q34578418 | ||
| Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy | Q34663691 | ||
| Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. | Q34712578 | ||
| Core-binding factors in haematopoiesis and leukaemia | Q34718183 | ||
| Transcriptome Profiling of Pediatric Core Binding Factor AML. | Q35784721 | ||
| Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. | Q35847967 | ||
| High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations | Q35849281 | ||
| Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia. | Q35877004 | ||
| Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice | Q35920680 | ||
| Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. | Q36166902 | ||
| Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation | Q36352394 | ||
| Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia | Q36373507 | ||
| In vivo live imaging of RNA polymerase II transcription factories in primary cells | Q36804109 | ||
| Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells | Q37123913 | ||
| Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma | Q37153719 | ||
| Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter | Q37347018 | ||
| Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia | Q37415483 | ||
| Core binding factor at the crossroads: determining the fate of the HSC. | Q37610919 | ||
| t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1 | Q37627380 | ||
| Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development | Q37704913 | ||
| Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects | Q37871413 | ||
| Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia | Q38287713 | ||
| AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. | Q38302335 | ||
| Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. | Q38317260 | ||
| Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. | Q38343552 | ||
| C/EBPα in normal and malignant myelopoiesis | Q38370875 | ||
| Wnt signaling induces transcription, spatial proximity, and translocation of fusion gene partners in human hematopoietic cells. | Q38422753 | ||
| Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia | Q38435682 | ||
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | Q38712298 | ||
| A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia | Q38738895 | ||
| miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia | Q38917442 | ||
| Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. | Q39093568 | ||
| Runx transcription factors in the development and function of the definitive hematopoietic system | Q39127010 | ||
| Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia | Q39485109 | ||
| Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia | Q39955606 | ||
| A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis | Q40246641 | ||
| KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival | Q40357255 | ||
| Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia | Q40405651 | ||
| Cytokine receptor signalling | Q40416594 | ||
| Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. | Q40453865 | ||
| Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera | Q40568990 | ||
| Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia | Q40719234 | ||
| The non-coding RNA landscape of human hematopoiesis and leukemia. | Q41331438 | ||
| Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. | Q53286270 | ||
| Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. | Q54295585 | ||
| The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell. | Q54332327 | ||
| The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation | Q57293716 | ||
| Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO | Q57615466 | ||
| The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia | Q57615556 | ||
| Functional genomic landscape of acute myeloid leukaemia | Q58598813 | ||
| Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit) | Q58772579 | ||
| Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16) | Q59511702 | ||
| Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias | Q59511707 | ||
| C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index | Q59538742 | ||
| In VivoDifferentiation of Mast Cells from Acute Myeloid Leukemia Blasts Carrying a Novel Activating Ligand-Independent C-kit Mutation | Q59538745 | ||
| ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion | Q59797105 | ||
| CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1 | Q64112901 | ||
| Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia | Q71099953 | ||
| Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia | Q71571086 | ||
| Secondary chromosomal abnormalities in acute leukemias | Q72528803 | ||
| The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia | Q73046772 | ||
| Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML | Q73230835 | ||
| C-kit mutations in core binding factor leukemias | Q73413358 | ||
| Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult | Q81152616 | ||
| GM-CSFRα: the sex-chromosome link to t(8;21)(+) AML? | Q83771893 | ||
| The role of CBFbeta in AML1-ETO's activity | Q84585440 | ||
| Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations | Q84698089 | ||
| High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome | Q87055437 | ||
| Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial | Q88548727 | ||
| MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts | Q88621594 | ||
| Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice | Q90782147 | ||
| Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features | Q91445211 | ||
| Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study | Q91713222 | ||
| HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia | Q91983203 | ||
| Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies | Q92114066 | ||
| Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia | Q92640684 | ||
| Transcriptional control of blood cell emergence | Q92740354 | ||
| Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1) | Q95811462 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P577 | publication date | 2019-12-07 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription | |
| P478 | volume | 11 |
Search more.